… from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. About … candidates and the timing thereof, including those in our innovation pipeline, statements regarding release of clinical …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3
LEIDEN, the Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 12:50pm ET.